Sayeh Tadayon

1.7k total citations · 1 hit paper
7 papers, 424 citations indexed

About

Sayeh Tadayon is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, Sayeh Tadayon has authored 7 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Pharmacology. Recurrent topics in Sayeh Tadayon's work include Metabolism, Diabetes, and Cancer (7 papers), Diabetes Treatment and Management (7 papers) and Pharmacology and Obesity Treatment (4 papers). Sayeh Tadayon is often cited by papers focused on Metabolism, Diabetes, and Cancer (7 papers), Diabetes Treatment and Management (7 papers) and Pharmacology and Obesity Treatment (4 papers). Sayeh Tadayon collaborates with scholars based in Denmark, United States and United Kingdom. Sayeh Tadayon's co-authors include Dorthe Skovgaard, Martin Friedrichsen, Astrid Breitschaft, Thomas K. Hansen, Steven P. Marso, Johannes F.E. Mann, Peter Rossing, Lawrence A. Leiter, Jochen Seufert and Thomas Idorn and has published in prestigious journals such as Diabetes, The Lancet Diabetes & Endocrinology and Diabetes Obesity and Metabolism.

In The Last Decade

Sayeh Tadayon

7 papers receiving 417 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

2020 269 citations Martin Friedrichsen, Astrid Breitschaft et al. Diabetes Obesity and Metabolism profile →

Peers

Sayeh Tadayon

EDM

MB

PHARM

SURGE

PHYSI

Thalia Panagiotopoulou Greece

Juan José Gorgojo Martínez Spain

Stanislava Macura Denmark

G. Kemmeries Germany

Lalita Prasad‐Reddy United States

Kristin C. Carlsson Petri Denmark

Christine Roy-Duval United States

Azazuddin Ahmed Romania

Disha Khemani United States

Rajaa Nahra United States

Thalia Panagiotopoulou Greece

Sayeh Tadayon

270 ×0.8

EDM

100 ×0.6

MB

105 ×0.6

PHARM

92 ×0.9

SURGE

73 ×0.9

PHYSI

Citations per year, relative to Sayeh Tadayon Sayeh Tadayon (= 1×) peers Thalia Panagiotopoulou

Countries citing papers authored by Sayeh Tadayon

Since Specialization

Citations

This map shows the geographic impact of Sayeh Tadayon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sayeh Tadayon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sayeh Tadayon more than expected).

Fields of papers citing papers by Sayeh Tadayon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sayeh Tadayon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sayeh Tadayon. The network helps show where Sayeh Tadayon may publish in the future.

Co-authorship network of co-authors of Sayeh Tadayon

This figure shows the co-authorship network connecting the top 25 collaborators of Sayeh Tadayon. A scholar is included among the top collaborators of Sayeh Tadayon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sayeh Tadayon. Sayeh Tadayon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Rubino, Domenica, Niclas Abrahamsson, Melanie J. Davies, et al.. (2021). Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4). Journal of the Endocrine Society. 5(Supplement_1). A63–A64. 3 indexed citations

2.

Mann, Johannes F.E., Thomas K. Hansen, Thomas Idorn, et al.. (2020). Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. The Lancet Diabetes & Endocrinology. 8(11). 880–893. 112 indexed citations

3.

Friedrichsen, Martin, et al.. (2020). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 23(3). 754–762. 269 indexed citations breakdown →

4.

Jendle, Johan, Andreas L. Birkenfeld, William H. Polonsky, et al.. (2019). Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials. Diabetes Obesity and Metabolism. 21(10). 2315–2326. 18 indexed citations

5.

Rodbard, Helena W., Luc Van Gaal, John Wilding, et al.. (2019). 1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction. Diabetes. 68(Supplement_1). 1 indexed citations

6.

Aroda, Vanita R., Matthew Capehorn, Louis Chaykin, et al.. (2019). Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials. Diabetes Obesity and Metabolism. 22(3). 303–314. 20 indexed citations

7.

Aroda, Vanita R., Jeffrey Unger, Bertrand Cariou, et al.. (2017). Semaglutide Consistently Reduces both Fasting and Postprandial Glucose Levels Across Sustain 1–5 Clinical Trials. Canadian Journal of Diabetes. 41(5). S52–S52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact